What happens when germs enter an eye-drop factory? Centre proposes stricter checks after Sun Pharma row

New Delhi: The Union Health Ministry has proposed stricter contamination control standards for sterile medicine manufacturing facilities in India. The proposed changes seek to align the country's pharmaceutical manufacturing rules with World Health Organization (WHO) guidelines.

The amendment, notified on October 28, targets Schedule M of the Drugs Rules, which sets standards for pharmaceutical manufacturing practices. It introduces stricter microbial contamination monitoring requirements for Grade A areas, the most critical cleanroom zones where exposed sterile products, containers and sterilised components are handled.

Under the proposed amendment, any microbial growth detected in Grade A areas must trigger an investigation. This would require manufacturers to examine contamination findings rather than simply record them without further action.

The proposal comes amid regulatory action against Sun Pharma following contamination concerns involving some of its ophthalmic products. On June 19, the All India Ophthalmological Society (AIOS) reportedly alerted its members about certain batches of the company's Predmet eye drops, which showed contamination consistent with Pseudomonas bacteria.

Predmet is a steroid-based eye drop prescribed for inflammatory eye conditions. Following the concerns, Sun Pharma withdrew the product and subsequently announced a wider recall of 11 ophthalmic products on July 17.

Regulators issued a show-cause notice to the company on August 10, citing alleged shortcomings in its quality management system. More recently, authorities ordered the suspension of eye-care drug production at its Assam manufacturing facility. The action followed the recall of 332 batches of ophthalmic products.

The contamination concerns have renewed questions about quality control and sterile manufacturing practices in India's pharmaceutical industry.

Why is the Centre tightening contamination rules?

India's existing Schedule M standards prescribe contamination limits for pharmaceutical manufacturing facilities. However, the requirements for Grade A cleanroom areas differ from WHO standards.

The proposed amendment aims to bring these requirements closer to international guidelines. Its key change is the requirement to investigate every microbial finding in Grade A areas.

These zones are particularly important because sterile medicines can become contaminated during manufacturing if environmental controls fail.

Eye drops require especially strict sterility standards because they are applied directly to the eyes. They are commonly prescribed for conditions such as glaucoma, infections, allergies and inflammation, as well as after eye surgery.

Pseudomonas bacteria can cause serious infections, including eye infections that may threaten vision. This makes contamination control particularly important in ophthalmic medicine production.

ALSO READ | Water contamination audit links 15 deaths to diarrhoea outbreak in Indore

What does the Sun Pharma case reveal about drug safety?

The Sun Pharma episode has brought renewed attention to the importance of manufacturing quality controls and regulatory oversight.

The company recalled multiple ophthalmic products after contamination concerns were raised. The subsequent regulatory action against its Assam facility has also highlighted the need for consistent monitoring of sterile manufacturing processes.

The issue is not limited to one manufacturer. India's pharmaceutical industry supplies medicines to domestic and international markets, making manufacturing standards important for both patient safety and export credibility.

The source report also notes that the US Food and Drug Administration had previously halted shipments from Sun Pharma's Halol facility in Gujarat following inspection-related concerns over contamination controls.

There is currently no clarity in the supplied report on whether patients experienced adverse effects after using the affected eye drops.

Why stricter sterile manufacturing rules matter

The proposed amendment reflects a wider regulatory challenge facing India's pharmaceutical sector: ensuring that medicines meet consistent quality and safety standards.

Sterile products, including eye drops and injectable medicines, require manufacturing environments with tightly controlled microbial contamination. Even a small lapse can create risks for patients.

Aligning Schedule M with WHO standards could strengthen India's manufacturing oversight and make contamination monitoring more stringent. Requiring investigations into every microbial finding in Grade A areas would also place greater responsibility on manufacturers to identify and address possible contamination sources.

However, the effectiveness of the proposed rules will depend on their implementation. Regular inspections, reliable laboratory testing, transparent reporting and corrective action will remain essential.

The Sun Pharma case also raises a larger question about whether existing quality-control systems are identifying manufacturing problems early enough. Stronger rules will matter only if pharmaceutical companies consistently follow them and regulators enforce them effectively.